BeiGene's PD-1 scores PhI­II win in esophageal can­cer — a 'key in­di­ca­tion' tapped by No­var­tis in $650M deal

Days af­ter bring­ing BeiGene’s PD-1 in­to its port­fo­lio, No­var­tis is adding a feath­er to its tislelizum­ab cap.

BeiGene re­port­ed that in the sec­ond-line set­ting, the check­point in­hibitor ex­tend­ed over­all sur­vival for pa­tients with esophageal squa­mous cell car­ci­no­ma, a key in­di­ca­tion iden­ti­fied by No­var­tis. It was the pri­ma­ry end­point in this Phase III tri­al.

“This is our fourth pos­i­tive Phase 3 read­out for tislelizum­ab and the first from our large Phase 3 pro­gram in gas­troin­testi­nal can­cers that al­so in­clude liv­er, stom­ach can­cers as well as esophageal can­cer,” BeiGene’s CMO in im­muno-on­col­o­gy, Yong Ben, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER